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Regenerative therapies hold a promising and exciting future for the cure of yet untreatable diseases, and mesenchymal stem cells
are in the forefront of this approach. However, the relative efficacy and the mechanism of action of different types of mesenchymal
stem cells are still incompletely understood.We aimed to evaluate the effects of human adipose- (hASC) and bone-marrow-derived
stem cells (hBMSCs) and adipose-derived stem cell conditioned media (ACM) on the viability of cardiomyoblasts in an in vitro
ischemia-reperfusion (I-R) model. Flow cytometric viability analysis revealed that both cell treatments led to similarly increased
percentages of living cells, while treatmentwithACMdidnot (I-Rmodel: 12.13±0.75%; hASC: 24.66±2.49%; hBMSC: 25.41±1.99%;
ACM: 13.94 ± 1.44%). Metabolic activity measurement (I-R model: 0.065 ± 0.033; hASC: 0.652 ± 0.089; hBMSC: 0.607 ± 0.059;
ACM: 0.225 ± 0.013; arbitrary units) and lactate dehydrogenase assay (I-R model: 0.225 ± 0.006; hASC: 0.148 ± 0.005; hBMSC:
0.146 ± 0.004; ACM: 0.208 ± 0.009; arbitrary units) confirmed the flow cytometric results while also indicated a slight beneficial
effect of ACM. Our results highlight that mesenchymal stem cells have the same efficacy when used directly on postischemic cells,
and differences found between them in preclinical and clinical investigations are rather related to other possible causes such as their
immunomodulatory or angiogenic properties.
1. Introduction
Regenerative therapies are representing a relatively new
possibility for the treatment of diseases where functional
tissue is lost. This approach is aiming to restore organ
functionality either by enhancing the resident stem cell
population or with substituting the damaged tissue with
added cells. Various cell types—such as embryonic, induced
pluripotent and adult stem cells—are used to this aim each
with its respective ethical, oncological, or immunological
advantages and disadvantages [1–4], but data from clinical
trials aremostly available fromadult stem cells, namely, bone-
marrow-derived stem cells (BMSCs) and adipose-derived
stem cells (ASCs) [5]. Adipose-derived stem cells have lately
become an attractive pool for autologous adult stem cells
because of their relatively easy harvest from patients via
minimally invasive liposuction [6, 7]. The use of these cells
showed promising results and sometimes great success in
various situations, such as in articular cartilage regeneration
[8], musculoskeletal tissue repair [9–11], and the treatment
of chronic, nonhealing wounds [12]. Considering cardiovas-
cular applications, several reports indicated a consistent and
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significant benefit from cell transplantation after myocardial
infarction in in vivo animal models [13–19]. Still, the clinical
trials using adult stem cell therapy in acute myocardial
infarction showed significant but only modest improvements
[20–22], and the relative efficacy of the different types of
mesenchymal stem cells is still incompletely understood [23,
24]. In this regard, Mazo et al. showed that the transplan-
tation of adipose-derived cells in chronic infarct provided
a better left ventricular heart function, less fibrosis, and
increased angiogenesis compared to bone-marrow-derived
stem cells [25]. Recently, Rasmussen et al. confirmed these
data using hypoxically preconditioned adipose- and bone-
marrow-derived stem cells from the same patient [26].
Thus, it seems that adipose-derived stem cells are superior
to mesenchymal stem cells of other origin. However, no
information is provided in these papers on the direct effects
of these cells on the postischemic cells. Furthermore, the
exact mechanism of action of these cells is also unclear. Initial
studies emphasized the role of cell fusion and differentiation
as the potentially most important mechanisms of actions
[27, 28], but subsequent studies questioned their impor-
tance in the beneficial effects [29, 30]. Interest, therefore,
switched towards paracrine factors involving proangiogenic,
antiapoptotic and anti-inflammatory pathways [31–34]. The
importance of the various paracrine effects is also emphasized
by the fact that improvements were found in experimental
models in spite of the very limited survival of the donor
cells in the hostile environment of a damaged tissue [35, 36].
Therefore, in the present study we aimed to evaluate the
direct effects of human adipose- and bone-marrow-derived
stem cells in a reductionist model of ischemia-reperfusion.
Furthermore, we wanted to investigate if mesenchymal stem
cells had any direct paracrine effect on the postischemic cells.
2. Methods
2.1. Cell Lines and Conditioned Media. H9c2 rat cardiomy-
oblast cell line was purchased fromATCC (Wesel, Germany).
Cells were cultured in high-glucose (4.5 g/L)DMEMcontain-
ing 10% fetal bovine serum, 4mM L-glutamine, 100U/mL
penicillin, and 100𝜇g/mL streptomycin at 37∘C in a humidi-
fied atmosphere of 5% CO
2
. Cell culture media was replaced
2 times a week, and cells were passaged once they reached
70–80% confluence.
Human adipose-derived stem cells (hASCs) were isolated
from liposuction samples of healthy female donors aged 22–
50 years (36.4 ± 4.5 years, 𝑛 = 5) who underwent elective
cosmetic liposuction after informed consent.The isolation of
hASCs from liposuction samples was performed according
to an established protocol [37, 38]. Briefly, lipoaspirates were
washed extensively with phosphate buffered saline (PBS)
and then incubated with 0.075% collagenase at 37∘C for 30
minutes. Enzyme activity was neutralized using Dulbecco’s
modified Eagle’s medium (DMEM; Gibco/Invitrogen, Carls-
bad, CA, USA) supplemented with 10% heat-inactivated fetal
calf serum (FCS), 100U/mL penicillin, 100𝜇g/mL strepto-
mycin (all Gibco/Invitrogen), and 100U/mLnystatin (Sigma-
Aldrich, St. Louis, MO, USA). Samples were centrifuged
at 1500 rpm for 10 minutes, and the resulting cell pellet
was plated in 75 cm2-culture flasks (Sarstedt Inc., Newton,
NC, USA). Cells were cultured in a 37∘C humidified 5%
CO
2
atmosphere. Nonadherent cells were removed after 24
hours. Cells were grown in antimycotic culture medium
for 7 days, and culture medium was changed every 2 to 3
days. After that period, hASCs were cultured in low-glucose
(1.0 g/L) DMEM containing 10% fetal calf serum, 4mM L-
glutamine, 100U/mL penicillin, and 100𝜇g/mL streptomycin
at 37∘C in a humidified atmosphere of 5% CO
2
. Cell culture
media was replaced 2 times a week, and cells were passaged
once they reached 70–80% confluence. Cryopreservation was
performed on hASCs prior to the experiments, and the
revitalized cells were used in the experiments. Passage 1 cells
were trypsinized and centrifuged at 1500 rpm for 10min.
Cell pellets were resuspended in CryoSafe medium (c. c. pro
GmbH, Neustadt, Germany), aliquoted to cryotubes (Nalge
Nunc, Roskilde, Denmark) as 1mL samples and were stored
for 40 minutes at −25∘C and then transferred to −80∘C for 24
hours followed by final cryopreservation in liquid nitrogen.
Human adipose-derived stem cells were characterized by
mesenchymal (CD90, CD105, and the stem cell antigen 1
(Sca-1) homolog CD59) and hematopoietic (CD34, CD45)
markers with flow cytometry in order to confirm their
lineage.
Human bone-marrow-derived stem cells (hBMSCs) were
isolated from samples gathered from young patients (aged
2–20) during standard orthopedic surgical procedures with
the informed consent of the patients or their parents under
approved ethical guidelines set by the Ethical Committee
of the Hungarian Medical Research Council. All procedures
were approved by the Ethical Committee of Semmelweis
University. Only such tissues were used that otherwise would
have been discarded. The bone marrow was flushed into
T75 flasks and diluted with low-glucose (1.0 g/L) DMEM
culture medium containing 10% FCS, 100U/mL penicillin,
100 𝜇g/mL streptomycin, and 4mM L-glutamine. The flasks
were incubated at 37∘C in fully humidified atmosphere of 5%
CO
2
and 95% air for 3 days. After the incubation period,
the hBMSCs adhered to the surface of the flasks and the
remaining components of bone marrow were eliminated by
washing with PBS. The used hBMSCs were cultured in the
same conditions as hASCs. Human bone-marrow-derived
stem cells were characterized bymesenchymal (CD73, CD90,
CD105, and CD166) and hematopoietic (CD34, CD45)mark-
ers with flow cytometry in order to confirm their lineage.
Characterization was performed on cells cultured under
standard culture conditions and growing asmonolayers while
displaying constant cell proliferation rates over the entire
culture period.
For preparing conditioned media (ACM) adipose-derived
stem cells were used because their proliferation capabilities
are much better compared to hBMSCs which helped to
achieve the highest possible concentrations of paracrine
molecules in the medium in the given period of time [39].
Human ASCs were seeded at 10.000 cells/cm2 in 100mm
Petri dishes using 8mL low-glucose (1.0 g/L) DMEM cul-
ture medium containing 10% FCS, 100U/mL penicillin,
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Figure 1: Ischemia-reperfusion model. (a) Representative fluorescent microscopic picture showing H9c2 cells injured with our ischemia-
reperfusion model and treated with Vybrant DiD (ex/em: 644/665 nm, blue) labeled cells. The cytoplasm of the living cells is stained with
calcein-AM (ex/em: 494/517 nm, green), the nuclei of the necrotic cells are ethidium homodimer-2 stained (ex/em: 536/624 nm, red). (b)
Flow cytometric histogram on the distinction between stem cells and H9c2 cells based on DiD staining. (c) Schematic representation of the
experimental protocol.
100 𝜇g/mL streptomycin, and 4mM L-glutamine. The dishes
were incubated at 37∘C in fully humidified atmosphere of 5%
CO
2
and 95% air, and cell-free supernatants were collected
for further experimental use after 48 hours.
2.2. In Vitro Ischemia-Reperfusion Model. Ischemia-reperfu-
sionwas simulated in vitro by oxygen and glucose deprivation
as described previously in our earlier publications [40–42].
Briefly, 30.000/well H9c2 cells in 12-well plates were incu-
bated in glucose-free DMEM in an atmosphere of 0.5% O
2
and 99.5%N
2
for 160minutes.This procedure was performed
on an established incubation system (PeCon, Erbach-Bach,
Germany). After incubation, the cells were reoxygenated and
glucose was provided by immediate replacement of themedia
with fresh high-glucose DMEM, and the cells were kept
in standard cell culture conditions till further experimen-
tal actions. Representative fluorescence microscopy pictures
were taken to follow the cell viability during the model using
a Zeiss LSM 510 META (Carl Zeiss, Jena, Germany). We
used calcein-AM (ex/em: 494/517 nm, Invitrogen, Carlsbad,
CA, USA) and ethidium homodimer-2 (ex/em: 536/624 nm,
Invitrogen, Carlsbad, CA, USA) labeling to mark live/dead
cells. Addedmesenchymal stem cells were dyed with Vybrant
DiD (ex/em: 644/665 nm, Invitrogen, Carlsbad, CA, USA)
(Figure 1(a)).
2.3. Experimental Protocol. Four experimental groups were
investigated in which postischemic cells received: (1) nor-
mal medium (I-R-model); (2) hASC conditioned medium
(ACM); (3) hASCs; and (4) a group that received hBMSCs.
Cell-treated groups were given 20.000 cells 30 minutes after
the reoxygenation, and the added cells were labeled with
Vybrant DiD fluorescent membrane dye to enable differen-
tiation from the postischemic cells (Figure 1(b)). Cells were
cocultivated for 24 hours in standard cell culture conditions.
In the case of ACM group at the end of simulated ischemia,
the glucose-freemediumwas changed to same volume of cell-
free hASC conditioned media (Figure 1(c)).
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2.4. Cell Viability Measurement with Flow Cytometry.
Twenty-four hours after reoxygenation, cells were harvested
by trypsinization and resuspended in 500𝜇L PBS containing
5 nM calcein-AM and 350 nM ethidium-homodimer-2 for
flow cytometric analysis [43]. Controls were prepared as
follows: for live control, cells were cultured in standard
conditions; for dead control, cells were treated with 100mM
H
2
O
2
for 1 hour immediately before trypsinization. For
the measurements, FACSCalibur flow cytometer (Becton
Dickinson, Franklin Lakes, NJ, USA) was used and the data
was analyzed with the Weasel program (The Walter and
Eliza Hall Institute, Parkville, VIC, Australia). Using flow
cytometry, we could distinguish the therapeutically given
cells from the postischemic cells on the basis of their DiD
labeling, and these cells were gated in or out as appropriate
for further analysis.
2.5. Metabolic Activity Measurement. For the evaluation of
the metabolic activity in the groups, we used the Presto-
Blue Cell Viability reagent (Invitrogen, Carlsbad, CA, USA),
according to the manufacturer’s instructions. Because of the
relative low cell numbers used in the experiments, we chose
a 24-hour incubation time in 37∘C and measured absorbance
as instructed.
In the hASC and hBMSC groups to exclude the influ-
ence of the added stem cells metabolism, we subtracted
the metabolic activity value of 20.000 stem cells from the
measured value. The obtained results are compared to the
metabolic activity of 30.000 H9c2 cells cultured in standard
cell culture conditions (control).
2.6. Lactate Dehydrogenase (LDH) Cytotoxicity Assay. The
measurement was performed using LDH Cytotoxicity Kit II
(PromoCell, Heidelberg, Germany) according to the manu-
facturer’s instructions, with 30-minute incubation period and
absorbance measurement at 490 nm. For the LDH measure-
ments, the previously described experimental groups were
used 24 hours after ischemia-reperfusion. The LDH enzyme
level was determined in the supernatant of 30.000 H9c2 cells
cultured in standard conditions (control). The absorbance
results were normalized with the total cell number in each
sample.
2.7. Statistics. Statistical analysis of data was carried out
either with one-way analysis of variance with Newman-
Keuls multiple comparison post hoc test or unpaired 𝑡-test as
appropriate. All data are expressed as mean± SEM. A 𝑃 value
of <0.05 was accepted as statistically significant.
3. Results
3.1. Characterization of hASCs and hBMSCs. Analyses of cell
surface markers by flow cytometry demonstrated that hASCs
(Figure 2(a)) were positive for the mesenchymal stromal
(stem) cell markers CD90 and CD105 as well as the stem
cell antigen 1 (Sca-1) homolog CD59 and were negative for
the lymphohaematopoetic markers CD34 and CD45. Flow
cytometry analysis of cultured bone-marrow-derived stem
cells (Figure 2(b)) exhibited the lack of hematopoietic mark-
ers (CD34−, CD45−), but revealedmesenchymal stem cell lin-
eage specific cell surface markers (CD73+, CD90+, CD105+,
and CD166+). With respect to cell surface marker expression,
our findings were consistent with previous reports [44, 45].
3.2. Flow Cytometric Viability Analysis. Our experimental
results regarding the postischemic cells showed that without
any treatment live cells amounted to 12.13 ± 0.75% after
24 hours. However, the percentage of live cardiomyoblasts
after 24 hours was significantly increased both with hASC
(24.66 ± 2.49%) and hBMSC (25.41 ± 1.99%) treatments but
not with the addition of ACM (13.94 ± 1.44%). There was no
significant difference between the cell-treated groups. Cell-
treatments led to a significantly increased percentage of live
cells compared to ACM treatment as well (Figure 3(a)).
The percentage of the dead cells in the I-R model group
was 87.71 ± 0.82%, while this was significantly smaller in
the hASC and hBMSC treated groups (hASC: 75.24 ± 2.49%;
hBMSC: 74.62 ± 1.99%), but was not statistically different in
the ACM treated group (ACM: 85.75 ± 1.57%).There was no
significant difference between the hASC- andhBMSC-treated
groups (Figure 3(b)).
Putting the added cells into consideration, we found
that most of the stem cells were alive in both the hASC-
treated group (70.30 ± 2.35%) and the hBMSC-treated group
(73.30 ± 1.92%), and there was no statistically significant
difference between the groups (Figure 3(c)). Furthermore, no
difference was found considering the dead cell population
(hASC: 29.20 ± 2.42%, hBMSC: 25.81 ± 1.89%; Figure 3(d)).
3.3. Metabolic Activity Measurement. Using the PrestoBlue
colorimetric assay, we strengthened our earlier findings with
the flow cytometric analysis. The reducing capability of the
cells reflecting their viability was significantly higher after
treatment with hASCs (0.652 ± 0.089AU, arbitrary units)
and hBMSCs (0.607 ± 0.059AU) compared to the I-R model
(0.065 ± 0.033AU). Moreover, the treatment with ACM was
also able to increase themetabolic activity of the postischemic
cells (0.225±0.013AU). No difference was observed between
the beneficial effects of the two different stem cell lines
(Figure 4(a)).
3.4. Lactate Dehydrogenase Cytotoxicity Assay. Cellular ne-
crosis expressed by LDH release decreased significantly com-
pared to I-Rmodel (0.225±0.006AU)when the postischemic
cells were treated with hASC and hBMSC (hASC: 0.148 ±
0.005AU; hBMSC: 0.146 ± 0.004AU). Conditioned media
could decrease the LDH levels only very slightly (0.208 ±
0.009AU). In case of hASC and hBMSC treatments, the
necrosis was not significantly different from the control
(Figure 4(b)).
4. Discussion
We report here that human adipose- and bone-marrow-
derived cells directly improve the survival of postischemic
cardiomyoblasts in an in vitro reductionist model. Metabolic
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Figure 2: Characterization of adult stem cells. Flow cytometric analysis revealed a CD34−, CD45− and CD59+, CD90+, CD105+ pattern for
hASCs (a) and a CD34−, CD45− and CD73+, CD90+, CD105+, CD 166+ pattern for hBMSCs (b). The isotype controls are indicated with
dashed lines.
6 Stem Cells International
0
10
20
30
I-R model ACM hASC hBMSC
Li
ve
 ce
lls
 (%
)
∗∗∗
∗∗∗
∗∗∗
∗∗
(a)
90
60
80
100
70
I-R model ACM hASC hBMSC
D
ea
d 
ce
lls
 (%
)
∗∗∗
∗∗∗
∗∗∗
∗∗
(b)
0
20
40
60
80
100
hASC hBMSC
Li
ve
 ce
lls
 (%
)
(c)
0
20
40
60
80
100
hASC hBMSC
D
ea
d 
ce
lls
 (%
)
(d)
Figure 3: Flow cytometric analysis of the postischemic cells and the therapeutic cells after 24 hours. Flow cytometric cell death analysis of
the postischemic cells revealed that cell treatment increased the percentage of live cells (a), while ACM did not (I-R model: 12.13 ± 0.75%;
ACM: 13.94 ± 1.44%; hASC: 24.66 ± 2.49%; hBMSC: 25.41 ± 1.99%). (b) The percentage of dead cells decreased when therapeutic cells were
added (I-R model: 87.71 ± 0.82%; ACM: 85.75 ± 1.57%; hASC: 75.24 ± 2.49%; hBMSC: 74.62 ± 1.99%). The percentages of live (c) and dead
(d) cells among the therapeutically added cells were not significantly different (𝑛 = 17–31, ∗∗𝑃 < 0.01, ∗∗∗𝑃 < 0.001).
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Figure 4:Metabolic activitymeasurement and LDH assay. (a)Themetabolic activitymeasured 24 hours after the ischemia-reperfusion injury
significantly decreased in the cells after the ischemic conditions compared to the control group, but the metabolic activity was enhanced with
all the applied treatments (control: 0.858±0.021AU; I-Rmodel: 0.065±0.033AU; ACM: 0.225±0.013AU; hASC: 0.652±0.089AU; hBMSC:
0.607±0.059AU; 𝑛 = 3, ∗𝑃 < 0.05, ∗∗∗𝑃 < 0.001). (b) LDH levels in the cell culture supernatant were significantly lower when ACM, hASC,
or hBMSC therapy was carried out (I-Rmodel: 0.225±0.006AU; ACM: 0.208±0.009AU; hASC: 0.148±0.005AU; hBMSC: 0.146±0.004AU;
𝑛 = 3, ∗𝑃 < 0.05, ∗∗∗𝑃 < 0.001). The stem cell treated groups are not significantly different from each other and also not different from the
control.
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activitymeasurement and the evaluation of necrosis strength-
ened the beneficial effect of cell treatment. Importantly, there
was no difference in these direct effects between the adipose-
and bone-marrow-derived stem cells.
Furthermore, the percentage of live mesenchymal stem
cells after 24 hours was the same, so their survival prop-
erties are also likely to be similar. These observations are
important because many publications indicate a better result
with adipose-derived stem cells, but the underlying mech-
anisms of action are not clearly understood yet, and, to
our knowledge, this is the first report on the comparison
of the direct effects of adult stem cells on the parenchymal
cells of the damaged tissue and on their survival in a
standardized situation. Rasmussen et al. have shown that
adipose-derived stem cells had preserved cardiac function
following myocardial infarction in their animal model while
bone-marrow-derived stem cells from the same source had
not [26]. They reported that neither of these cell types
induced angiogenesis. Thus, based on a recent report [39],
they argued that the potential difference between them
could be explained by differences in senescence properties
of the cells. Others showed in an investigation on spinal
cord injury that adipose-derived cells increased angiogen-
esis more than cells from other mesenchymal sources and
expressed higher amounts of VEGF while having similar
migration properties to the bone-marrow-derived stem cells
[46]. Adipose-derived stem cells were also found to be
more effective on cutaneous wounds upregulating fibroblast
migration and proliferation [47]. However, this may prove
to be problematic in case of myocardial regeneration due to
increased possibility of scar formation. Finally, a compara-
tive study indicated ASCs to be a more promising source
because of its more favorable immunomodulatory effects
[48].
We have drawn a few conclusions from our data on
the possible mechanisms of actions, also. First, LDH levels
decreased to control levels after cell treatment. This means
that necrosis was practically blocked by the added cells,
indicating that the dead cells in our study were apoptotic
cells. This is beneficial as apoptotic cells were shown to be
immunoregulatory, and some researchers argue that themain
effect of the current cytotherapy is aspecific and is the conse-
quence of this apoptotic pool [36]. However, it must be real-
ized that this possibility does not explain our results on cell
viability as ourmodel is completely reductionist and contains
no immune cells. Second, the conditioned medium slightly
increased metabolic activity and decreased LDH levels; thus,
it had an antinecrotic effect. It means that the paracrine
cocktail released from mesenchymal stem cells contains
substances that act directly on the ailing postischemic cells.
The enhanced metabolic activity may relate to slightly better
functionality of the surviving cells while the decreased LDH-
levels indicate that the postischemic cells are directed from
necrosis towards apoptotic cell death because the ACM
had no effect on the cell viability in the flow cytometric
measurements which is in accordance with our previous
work using bone-marrow-derived cells in cell culture inserts
[40].
In our study, the ineffectiveness of the stem cell condi-
tioned media versus the stem cell treatment in increasing
live cell numbers means either that the cell-cell contact
is particularly important in the direct beneficial effect or
the reached concentration of paracrine molecules is not
high enough for their effect. The importance of cell-cell
contact in the actions of therapeutically added cells was
highlighted in earlier studies where the mechanism was
related to intercellular tubular connections that potentially
lead to mitochondrial exchange between the cells [40, 49].
Cell fusion is another phenomenon which can be observed
in coculture studies, and in some cases it was also observed
in in vivo animal studies of stem cell grafting [30, 50, 51].
The possibility of cell fusion in our model was addressed
in our first publication and its frequency was found to be
extremely low [40]. However, it must be noted that the
extent of cell fusion shows extremely high variation among
different culture and detection techniques, and it cannot be
ruled out that extensive cell fusion is an in vitro artifact
[28, 52, 53]. Still, recent studies suggest that despite the low
frequency cell fusion may exert relevant impact on stem
cell programming or reprogramming in the heart [54]. In
view of the recent literature, it is more probable that the
mechanism is mediated via paracrine factors, but the stem
cells have to be induced by the microenvironment or by
contact with injured cells to release these beneficial factors
in necessary amounts. It is also possible that during the
production of the conditioned media the concentration of
paracrine factors in the conditioned media did not reach the
levels necessary to be effective. No wonder, studies of late
started to concentrate the conditioned medium to achieve
higher concentrations and found promising results [55]. Our
approach raises the possibility that the secreted molecules
are effective only in close proximity to the affected cells
where their local concentration can reach high levels. It
is highly possible that only direct cell-to-cell contact can
provide the necessary distance. It is interesting to note, that
such “microparacrine” mechanism exists in relation of stem
cells in the bone marrow, where the so-called “endosteal
niche-stem-cell synapses” are formed [56]. A final, additional
concern could be that conditioned media has a predominant
role in angiogenesis; thus, it is ought to be ineffective in our
reductionist model [26].
The relative role of the observed direct mechanism in the
in vivo setting is difficult to measure, but it may be quite
robust if we consider that we observed a doubling in the
number of live cells. However, it must be realized, that in our
experimentalmodel themajority of the therapeutically added
stem cells survived unlike the in vivo situation where most of
the injected cells die soon after the transplantation [36].Thus,
the added cells had a prolonged time for exerting their effect.
At this point, it may be useful to consider some exper-
imental points in our study. Our experimental model was
devised to investigate acute effects of therapeutic stem cells on
severely damaged cells to give room for the potential effects of
stem cells. For this reason, we have set the length of simulated
ischemia to a level where only 5–20%of cells survivedwithout
any treatment, which reflects the conditions found at the
site of the injury in the heart after myocardial infarction.
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We demonstrated the suitability of this model by detecting
significantly elevated levels of oxidative stress and cellular
necrosis after the simulation of ischemia-reperfusion in our
earlier publication [42].The effects were analyzed at 24 hours
because we wanted to rule out the potential differentiation
of the added stem cells, which occurs over longer time
periods.
Some limitations must be accounted for considering our
study. In our experiments, we used H9c2 cells which are
derived from rat embryonic heart tissue. Obviously, there are
differences between these cells and human adult cardiomy-
ocytes, but H9c2 cells are frequently used in studies dealing
with reperfusion injuries, and we have ample experience with
these cells in ourmodel [57–59]. Furthermore, as our aimwas
to analyze the direct effects of cells or media on postischemic
cells, using H9c2 cultures instead of adult cardiomyocyte cell
cultures we could avoid the possibility that inflammatory
cells would contaminate the cultures and affect the results.
Still, it has to be kept in mind that we used human cells for
treatment, but as no immune functions were involved in our
model this fact must not had any major effect on our results,
and human therapeutic cells are widely used in the literature
in animal disease models [60–62]. Also, in our experiments
we used an in vitro approach to the much more complex
issue of stem cell therapy in myocardial infarction, with all
the disadvantages and advantages of such model. An in vitro
transplantation model in a cell culture system cannot mimic
the 3-dimensional tissue where cell-to-cell connections are
different and it cannot reflect the complex (e.g., immuno-
logical) events taking place during and after myocardial
infarction. However, a limitation of the in vivomodels in cell
treatment studies is a lack of separation between the direct
effect on the treated parenchymal cells and the indirect effect
caused by alteration of the environment (e.g., inactivation
or reduced migration of leukocytes, angiogenesis, etc.). We
believe that our model was appropriate for the scope of
our study because it can focus on the direct effects of the
added cells on the postischemic cells. The similar benefits
achieved with hASC treatments strengthen that hASCs can
be an alternative to the most commonly used hBMSCs in the
emerging field of cell therapy. Subcutaneous adipose tissue is
an attractive source for obtaining autologous mesenchymal
stem cells as it can be harvested easily by liposuction which
is performed routinely on thousands of people per year. The
yield of stem cells per gram of adipose tissue is reported to be
superior to that which can be achieved per milliliter of bone
marrow [63], and adipose tissue can be harvested safely in
much higher quantity. This is important as stem cells consti-
tute only a small portion of cells in bone marrow and their
number and differentiation capacity correlate inversely with
age [64]. Similarly to hBMSCs, hASCs were shown to be able
to differentiate toward osteogenic, adipogenic,myogenic, and
chondrogenic lineages [6, 37, 64] and to secrete a host of
paracrine factors that can increase angiogenesis and act as
antiapoptotic signals [18, 31]. As their direct effects are at least
as good as the effects of hBMSCs, our results strengthen the
assumption that they constitute a better and more practical
source for therapies using adult stem cells. No evidence is
available to date, but two Phase I clinical trials have been
recently completed to test the safety and feasibility of adipose-
derived mesenchymal stem cell treatment in myocardial
infarction and in chronic myocardial ischemia (APOLLO,
NCT00442806; PRECISE, NCT00426868) [65].
5. Conclusions
Our results highlight that adipose-derived and bone-mar-
row-derived stem cell treatments can directly save damaged
cardiomyoblasts with the same efficacy. The survival of these
cells in the noxious, oxidative environment is also similar.
These results may indicate that if these cells arrive to the
injury site the resulting direct effect will be similar on the
cardiac cells so the observed differences in efficacy found
in in vivo experiments and in clinical trials may relate
to different properties in homing, angiogenesis induction,
fibroblast regulation, or immunomodulation.
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